Cytomed Therapeutics Limited Stock Analysis
| GDTC Stock | 2.96 0.47 13.70% |
CytoMed Therapeutics Limited is undervalued with Real Value of 3.7 and Target Price of 5.0. The main objective of CytoMed Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what CytoMed Therapeutics Limited is worth, separate from its market price. There are two main types of CytoMed Therapeutics' stock analysis: fundamental analysis and technical analysis.
The CytoMed Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and CytoMed Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
CytoMed |
CytoMed Stock Analysis Notes
About 69.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.22. CytoMed Therapeutics had not issued any dividends in recent years. To learn more about CytoMed Therapeutics Limited call the company at 65 6250 7738 or check out https://w2.cytomed.sg.CytoMed Therapeutics Quarterly Total Revenue |
|
CytoMed Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. CytoMed Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding CytoMed Therapeutics Limited or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| CytoMed Therapeutics is way too risky over 90 days horizon | |
| CytoMed Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 290.56 K. Net Loss for the year was (3.13 M) with profit before overhead, payroll, taxes, and interest of 355.19 K. | |
| CytoMed Therapeutics generates negative cash flow from operations | |
| About 69.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: CytoMed Therapeutics Leads 3 US Penny Stocks To Consider |
CytoMed Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CytoMed Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
CytoMed Largest EPS Surprises
Earnings surprises can significantly impact CytoMed Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-17 | 2023-09-30 | -0.06 | -0.08 | -0.02 | 33 |
CytoMed Therapeutics Environmental, Social, and Governance (ESG) Scores
CytoMed Therapeutics' ESG score is a quantitative measure that evaluates CytoMed Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of CytoMed Therapeutics' operations that may have significant financial implications and affect CytoMed Therapeutics' stock price as well as guide investors towards more socially responsible investments.
CytoMed Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.17 M.CytoMed Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.42) | (0.45) |
Management Efficiency
CytoMed Therapeutics has return on total asset (ROA) of (0.1744) % which means that it has lost $0.1744 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2626) %, meaning that it created substantial loss on money invested by shareholders. CytoMed Therapeutics' management efficiency ratios could be used to measure how well CytoMed Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 7, 2025, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.3. At present, CytoMed Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Net Tangible Assets are forecasted to decline to about 485.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.95 | 1.00 | |
| Net Current Asset Value | -1.8 M | -1.9 M | |
| Tangible Asset Value | 484.8 K | 460.6 K | |
| Tangible Book Value Per Share | 0.95 | 1.00 | |
| Enterprise Value Over EBITDA | (13.34) | (14.01) | |
| Price Book Value Ratio | 7.05 | 6.70 | |
| Enterprise Value Multiple | (13.34) | (14.01) | |
| Price Fair Value | 7.05 | 6.70 | |
| Enterprise Value | 39.2 M | 24.5 M |
Understanding the operational decisions made by CytoMed Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 7th of January, CytoMed Therapeutics shows the Downside Deviation of 5.44, risk adjusted performance of 0.1446, and Mean Deviation of 5.18. CytoMed Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.CytoMed Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. CytoMed Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for CytoMed Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
CytoMed Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CytoMed Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on CytoMed Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CytoMed Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Choo Chee Kong over a year ago CytoMed Therapeutics exotic insider transaction detected |
CytoMed Therapeutics Predictive Daily Indicators
CytoMed Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CytoMed Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 39575.27 | |||
| Daily Balance Of Power | (1.18) | |||
| Rate Of Daily Change | 0.86 | |||
| Day Median Price | 2.97 | |||
| Day Typical Price | 2.97 | |||
| Price Action Indicator | (0.25) | |||
| Period Momentum Indicator | (0.47) |
CytoMed Therapeutics Corporate Filings
6K | 6th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 5th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 20th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 7th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 3rd of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 30th of September 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 24th of June 2024 Other Reports | ViewVerify | |
6K | 20th of June 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
CytoMed Therapeutics Forecast Models
CytoMed Therapeutics' time-series forecasting models are one of many CytoMed Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CytoMed Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About CytoMed Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how CytoMed Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CytoMed shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as CytoMed Therapeutics. By using and applying CytoMed Stock analysis, traders can create a robust methodology for identifying CytoMed entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (9.70) | (10.18) | |
| Operating Profit Margin | (9.02) | (9.47) | |
| Net Loss | (9.70) | (10.19) | |
| Gross Profit Margin | 0.84 | 0.99 |
Current CytoMed Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CytoMed analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CytoMed analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 5.0 | Strong Buy | 1 | Odds |
Most CytoMed analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CytoMed stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of CytoMed Therapeutics, talking to its executives and customers, or listening to CytoMed conference calls.
CytoMed Stock Analysis Indicators
CytoMed Therapeutics Limited stock analysis indicators help investors evaluate how CytoMed Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading CytoMed Therapeutics shares will generate the highest return on investment. By understating and applying CytoMed Therapeutics stock analysis, traders can identify CytoMed Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 1.2 M | |
| Long Term Debt | 407.8 K | |
| Common Stock Shares Outstanding | 10.6 M | |
| Total Stockholder Equity | 8.5 M | |
| Tax Provision | 653.00 | |
| Property Plant And Equipment Net | 1.6 M | |
| Cash And Short Term Investments | 9 M | |
| Cash | 9 M | |
| Accounts Payable | 24.6 K | |
| Net Debt | -8.5 M | |
| 50 Day M A | 1.9693 | |
| Total Current Liabilities | 716.9 K | |
| Other Operating Expenses | 3.2 M | |
| Non Current Assets Total | 2.3 M | |
| Non Currrent Assets Other | 546.7 K |
Complementary Tools for CytoMed Stock analysis
When running CytoMed Therapeutics' price analysis, check to measure CytoMed Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytoMed Therapeutics is operating at the current time. Most of CytoMed Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytoMed Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytoMed Therapeutics' price. Additionally, you may evaluate how the addition of CytoMed Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |